Lane WS - Search Results

1

Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force.

Grunberger G, Abelseth JM, Bailey TS, Bode BW, Handelsman Y, Hellman R, Jovanovič L, Lane WS, Raskin P, Tamborlane WV, Rothermel C. Grunberger G, et al. Among authors: lane ws. Endocr Pract. 2014 May;20(5):463-89. doi: 10.4158/EP14145.PS. Endocr Pract. 2014. PMID: 24816754 No abstract available.

2

Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.

Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y. Rodbard HW, et al. Endocr Pract. 2014 Apr;20(4):285-92. doi: 10.4158/EP13287.OR. Endocr Pract. 2014. PMID: 24246344

3

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Buse JB, et al. Among authors: lane ws. Diabetes Care. 2018 Sep;41(9):1970-1980. doi: 10.2337/dc18-0343. Epub 2018 Jun 24. Diabetes Care. 2018. PMID: 29937430 Free PMC article. Clinical Trial.

4

Insulin Analogues and Hypoglycemia in Patients With Type 1 Diabetes-Reply.

Lane W, Bailey TS, Gerety G. Lane W, et al. JAMA. 2017 Nov 14;318(18):1828-1829. doi: 10.1001/jama.2017.14791. JAMA. 2017. PMID: 29136440 No abstract available.

5

High-dose insulin therapy: is it time for U-500 insulin?

Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS. Lane WS, et al. Endocr Pract. 2009 Jan-Feb;15(1):71-9. doi: 10.4158/EP.15.1.71. Endocr Pract. 2009. PMID: 19211405 Review.

6

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.

Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, Nielsen TSS, Warren M; Group Information; SWITCH 1. Lane W, et al. JAMA. 2017 Jul 4;318(1):33-44. doi: 10.1001/jama.2017.7115. JAMA. 2017. PMID: 28672316 Free PMC article. Clinical Trial.

7

Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance.

Lane WS. Lane WS. Endocr Pract. 2006 May-Jun;12(3):251-6. doi: 10.4158/EP.12.3.251. Endocr Pract. 2006. PMID: 16772195

8

Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.

DeVries JH, Bailey TS, Bhargava A, Gerety G, Gumprecht J, Heller S, Lane W, Wysham CH, Zinman B, Bak BA, Hachmann-Nielsen E, Philis-Tsimikas A. DeVries JH, et al. Diabetes Obes Metab. 2019 Mar;21(3):622-630. doi: 10.1111/dom.13565. Epub 2018 Nov 26. Diabetes Obes Metab. 2019. PMID: 30362250 Free PMC article.

9

A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance.

Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T. Lane WS, et al. Endocr Pract. 2010 Sep-Oct;16(5):778-84. doi: 10.4158/EP10014.OR. Endocr Pract. 2010. PMID: 20350913 Clinical Trial.

10

The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes.

Lane WS, Weinrib SL, Rappaport JM, Hale CB, Farmer LK, Lane RS. Lane WS, et al. Among authors: lane rs. Endocr Pract. 2013 Mar-Apr;19(2):196-201. doi: 10.4158/EP12226.OR. Endocr Pract. 2013. PMID: 23186973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

266 results

Search Page